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respiratory ectromelia virus (ECTV) infection, a surrogate mouse model for smallpox. TNF -23 /mice succumbed to fulminant disease whereas wild-type mice, and those expressing only 24 transmembrane TNF, recovered. TNF deficiency did not affect viral load or leukocyte 25 recruitment but caused severe lung pathology and excessive production of the cytokines IL-26 6, IL-10, TGF-b, and IFN-g. Blockade of these cytokines reduced lung pathology 27 concomitant with induction of protein inhibitor of activated STAT3 (PIAS3) and/or 28 suppressor of cytokine signaling 3 (SOCS3), factors that inhibit STAT3 activation. Short-29 term inhibition of STAT3 activation in ECTV-infected TNF -/mice with an inhibitor reduced 30 lung pathology. TNF is essential for regulating inflammation and its deficiency exacerbates 31 ECTV infection as a consequence of significant lung pathology caused by dysregulation of 32 inflammatory cytokine production, in part via overactivation of STAT3. 33
INTRODUCTION 35
Tumor necrosis factor (TNF) plays essential roles in normal physiology (Uysal et al., 1997) Subramaniam et al., 2013) . 47 TNF is produced following activation of the nuclear factor-kappa B (NF-kB) inflammatory 48 pathway, often in response to stress or infection. It is expressed as a transmembrane protein 49 (mTNF), which is then cleaved by metalloproteinase enzymes to produce the secreted form, 50 ( Figure S1A ). In lung homogenates of WT mice, sTNF was detectable from about day 7 p.i. 108 ( Figure S1B ) whereas mTNF was detectable earlier but levels of both forms were highest at 109 day 12 p.i. ( Figure S1C ). 110 WT, TNF -/and mTNF Δ/Δ mice were next infected i.n. with 25 plaque forming units (PFU) 111 of ECTV and assessed for clinical scores, weight loss, survival, viral load, NK cell and virus-112 specific CTL responses. 113
Evaluation of the clinical presentation using a scoring system (described in Table S1 ) 114 indicated that TNF -/animals fared significantly worse than WT or mTNF Δ/Δ mice beginning 115 at day 8 p.i. ( Figure 1A ). Mild clinical manifestations of infection were evident in all three 116 strains beginning at days 5 and 6 p.i., but only TNF -/mice showed postural changes and 117 inactivity from day 7. All 3 strains exhibited piloerection, lacrimation, and nasal discharge 118 from day 8 p.i., however, only TNF -/mice started to succumb to the infection, some with 119 apparent dyspnea. All strains lost weight from day 7 p.i., however, WT and mTNF Δ/Δ animals 120 started to recover from day 12 p.i. ( Figure 1B ). One mTNF Δ/Δ mouse died at day 9 whereas 121 all TNF -/mice succumbed between days 9 and 11 p.i. ( Figure 1C ). In some experiments, 122 TNF -/mice survived beyond 12 days but eventually succumbed to disease whereas WT and 123 mTNF Δ/Δ mice fully recovered. 124
Susceptibility to ECTV infection has been associated with uncontrolled virus replication in 125 all strains of mice studied to date (Chaudhri et al., 2004; Karupiah et al., 1993) . Although 126 TNF -/mice were susceptible to ECTV, they did not have increased viral load in the lung 127 ( Figure 1D ), liver ( Figure 1E ) or spleen ( Figure 1F ) compared to titers in either WT or 128 mTNF Δ/Δ animals at days 3, 5, 7 or 9 p.i. Conversely, mice deficient in IFN-a/b receptor 129 (IFN-a/bR -/-) or IFN-g (IFN-g -/-), strains known to rapidly succumb to mousepox due to 130 uncontrolled virus replication (Panchanathan et al., 2005) , had significantly higher viral load 7 in lungs compared to WT or TNF -/mice ( Figure 1G ). We investigated whether CrmD, the 132 vTNFR homolog encoded by ECTV, affected virus replication using the Naval strain of WT 133 (ECTV WT ) and CrmD mutant (ECTV ΔCrmD ) viruses (Alejo et al., 2018) . WT and TNF -/mice 134 infected with either of the viruses had comparable viral loads in lungs, indicating that vTNFR 135 did not affect viral replication ( Figure 1H To exclude the possibility that the increased susceptibility of TNF -/mice might be related to 145 the dysregulation of organogenesis and spatial organization of lymphoid tissue known to 146 occur during development (Korner et al., 1997; Neumann et al., 1996; Pasparakis et al., 1996; 147 Pasparakis et al., 1997), we used neutralizing anti-TNF mAb to treat ECTV-infected WT 148 mice. Compared to the control mAb-treated animals, mice treated with anti-TNF mAb 149 exhibited significantly higher clinical scores ( Figure S3A ) and 50% of the animals 150 succumbed by day 9 p.i. ( Figure S3B ). The histopathological scores were also higher in anti-151 TNF mAb-treated animals ( Figure S3C ) but there were no differences in viral load between 152 the groups ( Figure S3D ). Representative lung histology sections from naïve animals and 153 from ECTV-infected mice treated with either control or anti-TNF mAb are shown in Figure  154 S3E. These results are consistent with those in TNF -/mice and further confirmed that TNF is critical for recovery of mice from ECTV infection but that the cytokine has no antiviral 156 effects. 157
Exacerbation of lung pathology in the absence of of TNF 158
An examination of lung histological sections indicated that there were minimal changes in 159 the lungs of WT and mTNF Δ/Δ mice on days 3, 5, and 7 p.i., whereas edema was visible at 160 day 7 in TNF -/animals ( Figure S4A ). By day 9 p.i., edema and leukocyte extravasation were 161 seen in histological sections of all strains. Resolution of lung pathology was evident in WT 162 and mTNF Δ/Δ mice by day 11, but pathology worsened in TNF -/mice. As the clinical, Examination of the gross anatomy of uninfected and virus-infected lungs indicated TNF -/-167 lungs were more congested, boggier, physically larger, and contained more and bigger 168 necrotic lesions compared to WT lungs ( Figure 2A ). The lung wet-to-dry weight ratio 169 allowed assessment of fluid extravasation into the lung interstitial space, and our results 170 indicated that TNF -/lungs had significantly higher levels of fluid on days 7, 9, and 11 p.i. 171 ( Figure 2B ). Protein leakage is an indicator of increased vascular permeability, and TNF -/-172 lungs had significantly higher levels of protein in bronchoalveolar lavage fluid (BALF) at 173 day 11 p.i. compared to the WT lungs ( Figure 2C ). 174
Detailed microscopic examination of lung sections (Figures 2D and 2E) revealed that lung 175
pathology was more severe in virus-infected TNF -/mice. There was intra-alveolar and 176 perivascular edema in both strains but in the TNF -/group, the fluid extravasated to almost 177 the entire lobe leading to alveolar septal wall collapse by day 9. By day 11 p.i., resolution of 178 pathology was evident in WT lungs, wherein edema in the parenchyma started to clear, and restoration of the bronchial epithelial architecture was evident. In contrast, alveolar septal 180 wall damage and edema in TNF -/lungs continued to increase from day 9 to day 11 p.i., 181 parenchymal edema worsened, and the bronchial epithelia were completely denuded. The 182 histopathological differences between the infected lungs of both mouse strains were semi-183 quantified using a scoring system (described in Table S2 ). TNF -/lungs had significantly 184 higher scores than WT lungs on days 9 and 11 p.i. ( Figure 2F ). In WT mice, the histological 185 scores were lower at day 11 compared to day 9, consistent with recovery of this strain from 186 ECTV infection. TNF deficiency resulted in significant lung tissue damage and pathology, 187
suggesting that TNF plays a role in anti-inflammatory processes. 188
TNF is produced by many cell types and its deficiency does not affect leukocyte 189 recruitment to the lungs but results in dysregulated inflammatory cytokine production 190
Cell types responsible for TNF production within the infected lungs were identified by 191 immunohistochemistry ( Figures 3A and 3B) , and these were observed in the bronchial 192 epithelium and alveoli where the virus antigen was also present ( Figure S4B ). Although 193 morphologically identified leukocyte subsets were present in both strains of mice, as 194 expected TNF protein was not detected in TNF -/lungs ( Figure 3B ). Lungs from WT mice 195 showed that TNF protein was produced in response to infection by bronchial epithelial cells, 196 and by multiple leukocyte subsets ( Figure 3A ). Flow cytometric analysis of digested lungs 197 indicated that the total number of leukocytes (CD45 + ; Figure S5A ) or individual leukocyte 198 subsets ( Figure 3C ) were similar in both TNF -/and WT strains. Histological analysis of 199 TNF -/lungs suggested that there was a confluence of leukocytes in specific areas at day 11 200 p.i. (Figure 2E ), but the total number of leukocytes within the lungs had decreased compared 201 to day 9 p.i. (Figures S5A-S5C ). The consolidation of leukocytes in infected TNF -/mice 202 was therefore not related to an increase in their numbers per se but may have been due to dysregulated cytokine production. We, therefore, measured levels of some specific 204 inflammatory and regulatory cytokines in uninfected and virus-infected lung tissue. 205 TNF protein was not detected in TNF -/animals whereas it was detectable in WT mice at day 206 9 p.i., and levels increased substantially by day 12 p.i. ( Figure 3D ). This was also reflected 207 by TNF mRNA expression in WT animals ( Figure S5D ). Levels of IFN-g, IL-6, IL-10, and production of a number of inflammatory and regulatory cytokines with the potential to cause 213 lung damage. 214
Blockade of specific cytokine function dampens lung pathology 215
To ascertain whether the increased production of cytokines identified in Figure 3E -H 216 contributed to lung pathology, we reasoned that it might be possible to ameliorate the 217 pathology by neutralizing or blockading the function of each cytokine with specific mAb in 218 vivo. We used mAb against IFN-g, IL-6, IL-10R or TGF-b to block cytokine function at day 219 7 p.i., co-incident with histological evidence of pulmonary edema ( Figure S4A (Qing and Stark, 2004) . We reasoned that cytokine blockade may have reduced STAT3 250 signaling by decreasing levels of pSTAT3 expression or through the induction of PIAS3 or 251
SOCS3. 252
Western blot analysis revealed that levels of the inactive form of STAT3 were similar in 253 uninfected or infected mice regardless of mouse strain or mAb treatment ( Figure 5A ). 254
Minimal levels of pSTAT3 were detected in uninfected animals, and they increased by about 255 2-fold in WT mice and about 5-fold in TNF -/mice following infection ( Figures 5A and 5B ). 256
In WT mice, pSTAT3 levels increased further by about 2-fold with anti-IL-6 or anti-TGF-b 257 treatment, and higher than 3-fold following treatment with anti-IFN-g or anti-IL-10R 258 ( Figures 5A and 5B ). On the other hand, in TNF -/mice, the increases in pSTAT3 levels 259 above control IgG-treated groups were marginal. 260
The basal levels of PIAS3 were about 3-fold lower in TNF -/mice compared with WT 261 animals ( Figures 5A and 5C ). Infection augmented PIAS3 levels in both strains, with further 262 increases noted after blockade of cytokine function ( Figures 5A and 5C ). In TNF -/mice, the 263 PIAS3 band density increased by the largest magnitude following blockade of IL-6, IL-10R, 264
and TGF-b. The increase in PIAS3 levels may have contributed to dampening of pSTAT3 265 activity and as a consequence, reduction in lung pathology. 266 Naïve animals did not express SOCS3, and this protein was detectable at only low levels 267 after infection of both WT and TNF -/mice ( Figures 5A and 5D ). Only treatment with mAb 268 against IL-6 resulted in significant increases in levels of SOCS3 ( Figures 5A and 5D ). It is 269 likely that the combined actions of increased levels of PIAS3 and SOCS3 in the anti-IL-6-270 treated mice contributed to dampening of STAT3 activation and to effective amelioration of 271 lung pathology and survival of mice. 272
Inhibition of STAT3 activation ameliorates lung pathology 273
The preceding data suggested that it might be possible to dampen lung pathology through 274 inhibition of STAT3 activation. Treatment with S3I-201, a selective STAT3 inhibitor that 275 blocks STAT3 phosphorylation and dimerization (Chung et al., 1997), 7 days after ECTV 276 infection resulted in a significant reduction in clinical scores in WT ( Figure 6A ) and TNF -/-277 ( Figure 6B ) mice, and lung histopathological scores in both strains at day 9 p.i. ( Figure 6C ). 278
However, the treatment did not have any effect on viral load in either strain ( Figure 6D ). 279
Microscopically, STAT3 inhibitor treatment improved lung pathology in both WT ( Figure  280 6E) and TNF -/-( Figure 6F ) lungs, and the effects were similar to blockade of specific 281 cytokines ( Figure 4 ). These results indicate that dysregulated inflammatory cytokine 282 production and generation of lung immunopathology in the absence of TNF function is 283 associated, at least in part, with hyperactivation of STAT3. 284
Treatment with S3I-201 affected the levels of expression of a number of inflammatory 285 cytokines. In WT animals, which are able to recover from infection without significant lung 286 pathology, inhibitor treatment resulted in significant increases in the levels of mRNA for 287 TNF ( Figure 6G ), IL-10 ( Figure 6H ), TGF-b ( Figure 6I ), IFN-g ( Figure 6J ), IL-1a ( Figure  288 6K), IL-1b ( Figure 6L ), and IL-12p40 ( Figure 6M ). In sharp contrast, in TNF -/mice, which 289 exhibit severe lung pathology and succumb to infection, treatment with the STAT3 inhibitor 290 resulted in a significant reduction in the levels of some cytokine mRNA transcripts compared 291 to the mock-treated group. A reduction in mRNA levels was observed for IL-10 ( Figure 6H ), 292 IFN-γ ( Figure 6J ), and IL-12p40 ( Figure 6M ). Although levels of mRNA for IL-1β ( Figure  293 6L) and IL-6 ( Figure 6N ) were also reduced compared to the mock-treated group, they were 294 not statistically significant. Crucially, STAT3 inhibitor treatment reduced mRNA levels of a Therefore, the effect of STAT3 inhibition on the expression of mRNA transcripts for 297 inflammatory cytokines is dictated by the presence or absence of TNF. 298 TNF -/mice recover from ECTV infection after extended treatment with anti-IL-6 or 299
TGF-β 300
Short-term treatment with anti-cytokine mAb or STAT3 inhibitor significantly reduced lung 301 pathology in TNF -/animals. It was thus of interest to determine whether prolonged treatment 302 with these agents would allow TNF -/mice to recover from an otherwise lethal infection. 303
ECTV-infected TNF -/mice were treated with either a control mAb or mAb against IL-6, IL-304 10R or TGF-β beginning at day 7 p.i., and every 2 days thereafter until day 20 p.i. A separate 305 ECTV-infected group was treated with the STAT3 inhibitor from day 7 p.i. and every day 306 thereafter until day 20 p.i. All animals were monitored for 22 days. For virus load and 307 histopathological scores, organs were collected from animals that were moribund (and 308 euthanized for ethical reasons) or found dead before day 22 p.i., and those that were 309 sacrificed on day 22. Therefore, statistical analysis was not performed for virus load and 310 histopathological scores. 311
Control mAb-and anti-IL-10R-treated mice exhibited 100% mortality by days 10-13 p.i., 312 whereas animals treated with anti-IL-6 or anti-TGF-β survived the infection ( Figure 7A ). 313
Four of 5 animals treated with the STAT3 inhibitor died between days 11-18, and one animal 314 survived until the day of sacrifice. Extended treatment with anti-IL-10R did not improve 315 weight loss whereas all animals treated with anti-IL-6 or anti-TGF-β showed improvements 316 in body weights from day 13 ( Figure 7B 7C). Viral load in lungs of control mAb-, anti-IL-10R-or STAT3 inhibitor-treated mice were very high compared to titers in mice treated with anti-IL-6 or anti-TGF-b, which were close 321 to the limit of detection ( Figure 7D ). Viral load in the one mouse treated with the STAT3 322 inhibitor that survived was also below the limit of detection. 323
Histologically, only prolonged treatment with anti-IL-6 reduced lung pathology ( Figure 7E ). 324
All control mAb-, anti-TGF-b-or anti-IL-10R-treated mice and 4 of 5 STAT3 inhibitor-325 treated mice had significant lung pathology as revealed by the histopathological scores 326 ( Figure 7E ). The finding with anti-TGF-b treatment was surprising as even with this level of 327 pathology, the viral load was close to the limit of detection, the clinical scores were close to 328 baseline and the animals regained their loss in body weights. 329
The results indicate that the immune dysregulation and pulmonary pathology in TNF -/mice 330 following infection with ECTV were due to excessive production of some inflammatory and 331 regulatory cytokines and that blockade of those cytokines can protect mice from an otherwise 332 lethal infection. 333
DISCUSSION 334
TNF plays fundamental roles in homeostasis, acute inflammation and antimicrobial defense 335 but excessive or chronic production of the cytokine can cause serious pathology and 336 mortality. Paradoxically, our results have shown that TNF deficiency in mice also results in 337 significant pathology and death during mousepox, a surrogate model for smallpox. We also 338 established that mTNF alone was necessary and sufficient to protect against lung pathology 339 in ECTV infected mice. The immunopathology was not due to excessive leukocyte 340 infiltration into the lungs as numbers and phenotypes of leukocytes present in virus-infected 341 spleens of infected animals were not also affected in the absence of TNF. Both NK cell and 344 There are at least two reasons for the observed differences in the outcomes of infection with 434 the the mutant virus in the two strains of mice and these are discussed below. 435
First, the potent immune response generated by C57BL/6 mice can largely overcome the 436 effects of the various host response modifiers that ECTV encodes, including CrmD. 437 C57BL/6 mice produce significantly higher levels of TNF than BALB/c mice in response to 438 WT ECTV infection (Chaudhri et al., 2004). Our prediction is that in C57BL/6 mice infected 439 with the CrmD deletion mutant virus, we would expect to see further increases in TNF levels. 440
That is indeed the case as C57BL/6 mice develop significant lung pathology due to excessive infection, but the i.n. route is more sensitive, with virus replicating to high titers in the lungs, 450 and makes the resistant C57BL/6 strain succumb to mousepox at low doses of virus. 451
Curiously, we did not see any significant differences in the susceptibility of WT and TNF -/-452 C57BL/6 mice inoculated with varying doses of ECTV through the subcutaneous route (data 453 not shown). That finding suggested that a requirement for TNF to protect against ECTV 454 infection in C57BL/6 mice, specifically to regulate the local inflammatory response, depends 455 on the route through which virus is transmitted to the host. 456
In summary, TNF has no direct antiviral activity against ECTV but is necessary to regulate 457 lung inflammation. Respiratory ECTV infection of TNF -/mice caused lethal lung pathology 458 due to dysregulation and excessive production of some specific cytokines and overactivation 459 of STAT3. Short-term blockade of any of these cytokines with mAb or inhibition of STAT3 460 activation ameliorated lung pathology in ECTV-infected mice. Our data indicates that 461 targeting specific cytokines or cytokine signaling pathways to reduce or ameliorate lung 462 inflammation during a viral infection is possible but that the timing and duration of the Table S1 . 733 on days 0, 9 and 11 p.i. using a scoring system described in Table S2 . Data are expressed as 745 means ± SEM. For (B), (C) and (F), statistical analysis was undertaken using two-way 746 ANOVA followed by Holm-Sidak's multiple comparisons test. Results are representative of 747 3 separate experiments. See also Figure S3 and Table S2 . 748 experiments except for data shown in Figure 1H , for which the Naval strain of WT ECTV 833 (ECTV WT ) and the CrmD deletion mutant (ECTV ΔCrmD ) (Alejo et al., 2018) were used.
Viruses were propagated in BS-C-1 cells, semi-purified using a sucrose cushion and single-835 use aliquots were stored at -80ºC as described elsewhere in detail (Chaudhri et al., 2018) . 836
Virus infection, animal weights, clinical scores and treatments 837
Tribromoethanol-anesthetized mice (160-240 mg/kg i.p.) were infected through the i.n. route 838 with 25 PFU of ECTV in 30 µL PBS. Clinical manifestation of disease during ECTV 839 infection was assessed using the scoring system (Table S1) For ethical reasons, mice that were severely moribund and/or lost > 25% of the original body 848 weight were euthanized and considered dead the following day. 849
Histology and microscopic assessment of lung pathology 850
The left lobe of lung tissue was removed and fixed in 10% neutral-buffered formaldehyde at 851 room temperature for 24 h, embedded in paraffin, cut in 6 µm sagittal sections and stained 852 with hematoxylin and eosin (H&E) for analysis with a bright field microscope (Olympus IX 853 71). A semi-quantitative scoring system for lung pathology was developed (Table S2) with 854
Determination of cytokine protein levels 878
The levels of IFN-g, IL-6, IL-10 and TNF in the lung homogenates were measured using the 879 Mouse Inflammation Cytokine Bead Array Kit (BD Biosciences) according the 880 manufacturer's protocol. Acquisition of data was done using a BD FACSCalibur flow 881 cytometer with BD Cell Quest software. Data were analyzed using FlowJo Software version 882 9.5. TGF-b levels were measured using capture ELISA kits (Biolegend), performed 883 according to the manufacturer's protocol. Optical density was measured at 450 nm with 884 SOFTmax Pro software (Molecular Devices Corp). 885
SDS PAGE and Western blot analysis 886
Lung homogenates and a pre-stained recombinant protein ladder (Bio-Rad) were run in a 887 12% SDS-polyacrylamide gel and were transferred to a nitrocellulose membrane (Bio-Rad). 888
After blocking with 1 M glycine, 5% w/v dry skim milk blocking solution, the membrane 889 was incubated with primary antibody (STAT3, polyclonal 
Immunohistochemistry of lung sections 897
Immunohistochemistry was performed on formaldehyde-fixed and paraffin-embedded lung 898 sections. Samples were deparaffinized and rehydrated through different concentrations of 899 xylene and ethanol, followed by antigen retrieval in Tris/EDTA Buffer. The sections were 900 incubated in primary TNF antibody (MP6-XT3, rat IgG1) and secondary HRP-conjugated goat anti-rat IgG (Santa Cruz Biotechnology, cat. no. sc-52619 and sc-2006, respectively). 902
The reaction was developed using a 3,3'-diaminobenzidine substrate buffer and 903 counterstained with H&E for analysis with a bright field microscope (Olympus IX 71). 904
905

RNA extraction 906
Lung tissue from individual mice were homogenized in 1 mL of TRIsure reagent with 907 TissueLyser II (Qiagen, cat. no. 853000) and as per the manufacturer's instructions and 908 samples were centrifuged for 15 min at 12,000 x g at 4 o C to remove cellular debris. In the 909 final step, RNA pellets were air-dried and resuspended in 30-50 µL RNAse-free water and 910 incubated for 10 min at 60 o C to ensure they were dissolved. RNA concentration was 911 determined using a Nanodrop ND-1000 spectrophotometer. cells that were either uninfected or infected with ECTV (10 PFU/cell) were labelled with 939 20 µCi 51 Cr (Na2 51 CrO4) and incubated in a humidified atmosphere of 5% CO2 and 95% air 940 for 1 h. Cells were washed three times and resuspended in complete medium and 2 x 10 4 941 cells were added into wells of U-bottom 96-well plates. Effector cells (single cell 942 suspensions of digested lungs or splenocytes) were added to wells with target cells in 943 triplicate to obtain effector cell:target cell ratios of 100:1, 33:1, 11:1 and 3.7:1. Control wells 944 included target cells only (spontaneous release) or target cells plus 1% Triton X (maximum 945 release). After incubation for 6 h in a humidified atmosphere of 5% CO2 and 95% air, the 946 96-well plates were centrifuged at 300 x g for 5 min, and 25 µl of supernatant from each well 947 was transferred to a corresponding well in Luma-96 plate (Perkin-Elmer, Boston, USA). For NK cell responses, YAC-1 target cells were used without the need for infection with 958 ECTV. YAC-1 cells were labelled with 51 Cr as described for MC57G cells. Effector and 959 target cells were incubated for 4 h after which supernatants were collected to determine cpm 960 as described for the CTL assay. 961
Statistical analysis 962
Statistical analyses of experimental data, as indicated, were performed using GraphPad 963 Prism 8 (GraphPad Software, Inc.). A p value of <0.05 was taken to be significant, *, p ≤ 964 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. Log-rank (Mantel-Cox) test, two-tailed 965
Mann-Whitney test, unpaired t-test with Holm-Sidak's correction and two-way ANOVA 966 with Holm-Sidak's correction for multiple comparison were used to compare results. 967 
